Clinical Trials Browser

Prostatic Neoplasms

Psychological Well-Being, Prostatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Kidney Neoplasms, Wilms Tumor

Prostatic Neoplasms

Urinary Bladder Neoplasms, Prostatic Neoplasms, Renal Insufficiency, Acute Kidney Injury

Prostatic Neoplasms

Emergence Delirium, Carcinoma, Renal Cell, Prostatic Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Renal Cell

Kidney Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Lipodystrophy, Congenital Generalized

Carcinoma, Renal Cell

Prostatic Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Prostate Cancer Patients Treated by Radiotherapy

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Disease, Prostatic Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Kidney Neoplasms, Neoplasms

Prostate Adenocarcinoma

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Carcinoma, Renal Cell

Prostatic Neoplasms

Urinary Bladder Neoplasms

Urothelial Bladder Carcinoma

Carcinoma, Renal Cell

Localized Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Renal Cell

Urinary Bladder Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Prostatic Neoplasms, Stress Disorders, Post-Traumatic, Colorectal Neoplasms

Kidney Neoplasms

Clinical Trials

PREPARE SBRT

PC-PEP

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

Evaluation of an Active Surveillance Protocol for Prostate Cancer in the Brazilian Population

MetroWilms

Mechanisms of Resistance to PSMA Radioligand Therapy

Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery

COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

BioPro-RCMI

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

64Cu-GRIP B in Patients With Advanced Malignancies

TARGET-RCC

A Study of Tarlatamab for People With Prostate Cancer

Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

OASIS

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

INSIGHT-PCa

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

ANDARP

RADVAN

CHAS3

FRISC

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Bladder Bank (a Prospective Banking Study)

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

EXACT

Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial

Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

PRORAND

RASROP-003

UroDNA

PSMA-VISION

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Low-flow Versus Minimal-flow Sevoflurane Anesthesia During Robot-assisted Laparoscopic Radical Prostatectomy

CKNO-PRO

NeuroPrevPTSD

SPECT/CT for the Characterization of Renal Masses